Literature DB >> 17190616

Structural models of amyloid-like fibrils.

Rebecca Nelson1, David Eisenberg.   

Abstract

Amyloid fibrils are elongated, insoluble protein aggregates deposited in vivo in amyloid diseases, and amyloid-like fibrils are formed in vitro from soluble proteins. Both of these groups of fibrils, despite differences in the sequence and native structure of their component proteins, share common properties, including their core structure. Multiple models have been proposed for the common core structure, but in most cases, atomic-level structural details have yet to be determined. Here we review several structural models proposed for amyloid and amyloid-like fibrils and relate features of these models to the common fibril properties. We divide models into three classes: Refolding, Gain-of-Interaction, and Natively Disordered. The Refolding models propose structurally distinct native and fibrillar states and suggest that backbone interactions drive fibril formation. In contrast, the Gain-of-Interaction models propose a largely native-like structure for the protein in the fibril and highlight the importance of specific sequences in fibril formation. The Natively Disordered models have aspects in common with both Refolding and Gain-of-Interaction models. While each class of model suggests explanations for some of the common fibril properties, and some models, such as Gain-of-Interaction models with a cross-beta spine, fit a wider range of properties than others, no one class provides a complete explanation for all amyloid fibril behavior.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17190616     DOI: 10.1016/S0065-3233(06)73008-X

Source DB:  PubMed          Journal:  Adv Protein Chem        ISSN: 0065-3233


  57 in total

Review 1.  Polyglutamine misfolding in yeast: toxic and protective aggregation.

Authors:  Martin L Duennwald
Journal:  Prion       Date:  2011-10-01       Impact factor: 3.931

2.  Amyloid β-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process.

Authors:  Erik Hellstrand; Barry Boland; Dominic M Walsh; Sara Linse
Journal:  ACS Chem Neurosci       Date:  2009-10-09       Impact factor: 4.418

Review 3.  Emergence and natural selection of drug-resistant prions.

Authors:  James Shorter
Journal:  Mol Biosyst       Date:  2010-04-27

4.  The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines.

Authors:  Silvia Lisa; Massimiliano Meli; Gema Cabello; Ruth Gabizon; Giorgio Colombo; María Gasset
Journal:  Cell Mol Life Sci       Date:  2010-05-09       Impact factor: 9.261

Review 5.  The structural biology of protein aggregation diseases: Fundamental questions and some answers.

Authors:  David Eisenberg; Rebecca Nelson; Michael R Sawaya; Melinda Balbirnie; Shilpa Sambashivan; Magdalena I Ivanova; Anders Ø Madsen; Christian Riekel
Journal:  Acc Chem Res       Date:  2006-09       Impact factor: 22.384

6.  Defined DNA sequences promote the assembly of a bacterial protein into distinct amyloid nanostructures.

Authors:  Rafael Giraldo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-24       Impact factor: 11.205

7.  Probing the mechanisms of fibril formation using lattice models.

Authors:  Mai Suan Li; D K Klimov; J E Straub; D Thirumalai
Journal:  J Chem Phys       Date:  2008-11-07       Impact factor: 3.488

Review 8.  Structural basis of infectious and non-infectious amyloids.

Authors:  Ulrich Baxa
Journal:  Curr Alzheimer Res       Date:  2008-06       Impact factor: 3.498

9.  Conformational switching in PolyGln amyloid fibrils resulting from a single amino acid insertion.

Authors:  Rick K Huang; Ulrich Baxa; Gudrun Aldrian; Abdullah B Ahmed; Joseph S Wall; Naoko Mizuno; Oleg Antzutkin; Alasdair C Steven; Andrey V Kajava
Journal:  Biophys J       Date:  2014-05-20       Impact factor: 4.033

10.  Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases.

Authors:  Rodrigo Morales; Lisbell D Estrada; Rodrigo Diaz-Espinoza; Diego Morales-Scheihing; Maria C Jara; Joaquin Castilla; Claudio Soto
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.